The closing price of Maravai LifeSciences Holdings Inc (NASDAQ: MRVI) was $8.02 for the day, down -2.91% from the previous closing price of $8.26. In other words, the price has decreased by -$0.24 from its previous closing price. On the day, 2211464 shares were traded.
Ratios:
Our analysis of MRVI’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.83 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 6.51. For the most recent quarter (mrq), Quick Ratio is recorded 8.33 and its Current Ratio is at 8.96. In the meantime, Its Debt-to-Equity ratio is 1.18 whereas as Long-Term Debt/Eq ratio is at 1.16.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, BofA Securities on December 12, 2023, Upgraded its rating to Buy and sets its target price to $8 from $10 previously.
Credit Suisse Downgraded its Outperform to Neutral on May 23, 2023, whereas the target price for the stock was revised from $18 to $14.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MRVI now has a Market Capitalization of 1.06B and an Enterprise Value of 1.10B. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.67 while its Price-to-Book (P/B) ratio in mrq is 2.04. Its current Enterprise Value per Revenue stands at 3.79 whereas that against EBITDA is 1.65.
Stock Price History:
Over the past 52 weeks, MRVI has reached a high of $16.62, while it has fallen to a 52-week low of $4.52. The 50-Day Moving Average of the stock is 6.21, while the 200-Day Moving Average is calculated to be 9.03.
Shares Statistics:
MRVI traded an average of 2.52M shares per day over the past three months and 5.53M shares per day over the past ten days. A total of 131.69M shares are outstanding, with a floating share count of 106.65M. Insiders hold about 19.32% of the company’s shares, while institutions hold 86.16% stake in the company. Shares short for MRVI as of Feb 15, 2024 were 6.21M with a Short Ratio of 2.46, compared to 6.63M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 4.70% and a Short% of Float of 5.63%.
Earnings Estimates
The firm’s stock currently is rated by 10 analysts. On average, analysts expect EPS of -$0.03 for the current quarter, with a high estimate of -$0.02 and a low estimate of -$0.03, while EPS last year was $0.03. The consensus estimate for the next quarter is -$0.01, with high estimates of $0.01 and low estimates of -$0.02.
Analysts are recommending an EPS of between $0.03 and -$0.06 for the fiscal current year, implying an average EPS of -$0.02. EPS for the following year is $0.05, with 11 analysts recommending between $0.12 and -$0.01.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 9 analysts. It ranges from a high estimate of $62.2M to a low estimate of $58.7M. As of the current estimate, Maravai LifeSciences Holdings Inc’s year-ago sales were $79.03M, an estimated decrease of -23.40% from the year-ago figure. For the next quarter, 9 analysts are estimating revenue of $66.95M, a decrease of -2.80% over than the figure of -$23.40% in the same quarter last year. There is a high estimate of $69M for the next quarter, whereas the lowest estimate is $63M.
A total of 12 analysts have provided revenue estimates for MRVI’s current fiscal year. The highest revenue estimate was $278.47M, while the lowest revenue estimate was $265M, resulting in an average revenue estimate of $272.66M. In the same quarter a year ago, actual revenue was $288.94M, down -5.60% from the average estimate. Based on 12 analysts’ estimates, the company’s revenue will be $301.45M in the next fiscal year. The high estimate is $329.31M and the low estimate is $284.72M. The average revenue growth estimate for next year is up 10.60% from the average revenue estimate for this year.
